Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Expression Pathology’s Liquid Tissue Patent Issues in Japan

Published: Tuesday, September 28, 2010
Last Updated: Tuesday, September 28, 2010
Bookmark and Share
Patent covers tissue processing methods to enable discovery and accurate measurement of protein biomarkers in standard FFPE tissue by mass spectrometry.

Expression Pathology Inc. announced that the Japan Patent Office has issued patent number 4579234 which covers methods for preparing tissue for protein analysis, including the company’s proprietary Liquid Tissue® sample preparation methodology.

The claims of the patent are directed to tissue processing methods that enable discovery and accurate measurement of protein biomarkers in standard formalin-fixed paraffin-embedded (FFPE) tissue by mass spectrometry and other methods.

Formalin fixation is the standard process used worldwide to preserve biopsies and surgical tissue, but it limits the ability to accurately measure and study proteins and changes in protein pathways in cancers and other diseases. Liquid Tissue® sample preparation produces a solution that is representative of the total protein content of an FFPE sample, enabling application of powerful mass spectrometry techniques to proteomic profiling and targeted quantitation of proteins and protein activation, such as phosphorylation.

“This is an important milestone for our company”, says Casey Eitner, President and CEO of Expression Pathology. “Accurate multiplex protein assays that can be run on standard FFPE tissue are part of the future of personalized medicine. We are combining our technologies with latest developments in mass spectrometry to develop assays that can simultaneously measure the key targets in tumor signaling networks associated with specific prognostic and drug treatment decisions. The Japanese patent extends protection for our technology to one of the world’s most important medical and scientific markets”.

Expression Pathology is represented by AMR Inc. in Japan. Mr. Yasuhiko Bando, Chief Strategic Officer at AMR says: “We provide novel proteomic and biomarker analysis platforms including sample preparation and LC/MS systems for clinical samples. The products and assays based on the Liquid Tissue patent are of great interest to clinical and medical fields in Japan. We are already collaborating with several leading institutions in Japan, including Tokyo Medical University, Tohoku University and National Cancer Center, who are using Liquid Tissue® technology in leading edge research. With this technology we are now able to provide a seamless solution for the analysis of clinical tissue samples.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Expression Pathology Obtains Second U.S. Liquid Tissue® Patent
Patent cover methods that increase the range of proteins and protein modifications which can be analyzed using the company’s patented Liquid Tissue® method.
Sunday, April 10, 2011
Expression Pathology Provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
The Liquid Tissue®-SRM Technology accelerates identification of cancer molecular markers for developing more effective treatments.
Wednesday, January 12, 2011
Expression Pathology provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
Expression Pathology Inc. announced an agreement with Roche wherein Expression Pathology will provide its Liquid Tissue®-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.
Tuesday, January 11, 2011
Flagship Partners with Expression Pathology to Combine Tissue Proteomics and Digital Pathology
Two leading companies offer clients integrated services for digital pathology and quantitative mass-spec based tissue proteomics.
Sunday, December 12, 2010
Key U.S. Patent Issues on Expression Pathology’s Liquid Tissue® Technology
The patent claims methods to enable protein analysis in FFPE tissue for clinical research and diagnostics.
Wednesday, January 07, 2009
Expression Pathology to Collaborate in $300,000 Alberta Breast Cancer Research
EPI will employ its tissue proteomics technologies to identify protein biomarkers of metastasis.
Tuesday, September 30, 2008
EPI Licenses Harvard’s AQUA™ Peptide Technology
Company licenses the patent rights for mass spectrometry quantitation of proteins in patient tissue.
Wednesday, August 30, 2006
Publication Shows Cancer Biomarker Identification in Formalin-Fixed Tissue
The article describes LC MS/MS mass spectrometry analysis of FFPE prostate cancer tissue.
Thursday, November 10, 2005
Scientific News
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
Massive Helium Discovery a "Game Changer" for Medical Industry
A new development is gas exploration has yielded the discovery of a huge helium gas field, which could help relieve the dwindling supply.
Unidentified Spectra Detector
New algorithm clusters over 250 million spectra for analysis, such that millions of unidentified peptide sequences can be recognised.
Making Metabolite Identification More Efficient
Metasense combines the industry's most-comprehensive metabolic transformation prediction with efficient analysis of LC/MS analytical measurements to identify, visualize, and report chemical biotransformations.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!